Andere Sprachen Recursion Pharmaceuticals, Inc.

Aktien

A3CM1C

US75629V1044

RXRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:08 17.05.2024			% 5 Tage	% 1. Jan.
9.415 ^USD	-1.00%		+9.48%	-4.51%

13.05.	Recursion Pharmaceuticals meldet Fertigstellung des BioHive-2 AI Supercomputers	MT
10.05.	Recursion Pharmaceuticals Q1 Verlust weitet sich aus, Umsatz steigt	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Recursion Pharmaceuticals Says BioHive-2 AI Supercomputer Completed	13.05.
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry	13.05.
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry	13.05.
Recursion Pharmaceuticals Q1 Loss Widens, Revenue Rises	10.05.
Recursion Pharmaceuticals: Q1 Earnings Snapshot	09.05.
Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q1 Revenue $13.8M, vs. Street Est of $12.7M	09.05.
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results	09.05.
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9	02.05.
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9	02.05.
Recursion to Participate in Upcoming Investor Conferences	01.05.
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program	30.04.
Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	18.04.
Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	16.04.
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer	16.04.
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer	16.04.
Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer	16.04.
Recursion to Participate in Upcoming Investor Conference	02.04.
Recursion to Participate in Upcoming Investor Conference	02.04.
Recursion Publishes Annual Environmental, Social and Governance Report	26.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Recursion Pharmaceuticals, Inc.

Aktien

A3CM1C

US75629V1044

RXRX

Andere Sprachen

Filter